Skip to main content

Industrial Environmental Management Systems

BayBiotech.NET
Environmental Management Systems (EMS) can be considered as a tool to manage the environmental quality policies and procedures as per Industry standards and regulatory guidelines. EMS provides a framework to efficiently operate organizational responsibilities and activities in most efficient ways keeping the risk to the environment at its minimum. EMS also provides scope to the organization to implement corrective and preventive plan in order to continuously improve the environmental performance. An effective management system ensures that adequate efforts are properly deployed in regard to training, monitoring and reporting.

Three main environmental guidelines that fall within the scope of Biotech/ Life Sciences Industry and will need integration with EMS are:

RC14001: Responsible Care® (RC) is a voluntary initiative of the worldwide chemical industry with a focus on an on-going efforts to improve the safety and the protection of health and the environment, applicable not only to the organization but to the entire supply chain. The program was first introduced in 1988 by the American Chemistry Council (ACC) to address public concerns about the manufacture and use of chemicals and so far has been adopted in over 45 countries. To further strengthen the program,
ACC integrated the Responsible Care® requirements into the globally accepted Environmental Management Standard, ISO 14001.Responsible Care® principles in some form or other have been long adopted by leading organizations in the chemical industry. (http://www.techstreet.com/)
OHSAS18001: OHSAS 18001 standards were created by concerted efforts of the world’s leading national standards bodies, certification bodies, and specialists for occupational health and safety standards. The OHSAS specification is applicable to any organization that wishes to establish an OH&S management system to eliminate or minimize risk to employees and other interested parties who may be exposed to OH&S risks associated with its activities and provides guidelines to implement maintain and improve an OH&S management system.( http://www.osha-bs8800-ohsas-18001-health-and-safety.com/ohsas-18001.htm)
ISO14001: The ISO 14000 family addresses various aspects of environmental management. The very first two standards, ISO 14001:2004 and ISO 14004:2004 deal with environmental management systems (EMS). ISO 14001:2004 provides the requirements for an EMS and ISO 14004:2004 gives general EMS guidelines.
 ISO 14001:2004 provides a generic requirement for an environmental management system. The underlying philosophy is that whatever the organization's activity, the requirements of an effective EMS are the same, whereas:
 ISO 14004:2004 provides guidelines on the elements of an environmental management system and its implementation, and discusses principal issues involved. (http://www.iso.org/)

Comments

Post a Comment

Popular posts from this blog

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!
Post a Comment
Read more

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...
Post a Comment
Read more

Amendments for High Risk Device Type Regulatory Pathway

BayBiotech.NET Government Accounting Office (“GAO”) has issued a long-awaited report evaluating the use of the 510(k) process by the Food and Drug Administration (“FDA” or the “Agency”) in the January of 2009. Report mainly focused on Preamendment class III devices. Although most high-risk class III medical devices are subject to the demanding premarket approval (“PMA”) process, preamendment class III devices may be cleared through the 510(k) pathway until FDA issues regulations requiring a PMA. Under the Safe Medical Devices Act of 1990, FDA was required either to reclassify preamendment class III devices into class I or II, or (2) issue regulations requiring PMA approval for the devices, GAO noted that 20 preamendment class III device types have not yet been addressed by the Agency. GAO has urged FDA to take required steps to address the remaining class III devices that continue to be eligible for 510(k) review. As a result of the report, FDA has committed to address al...
Post a Comment
Read more